Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
NVO Analyst Ratings
Hold
3 Buy
4 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NVO Stock 12 Month Forecast
Average Price Target
$92.54
▲(24.00%Upside)
| Highest Price Target$139.25 | Average Price Target$92.54 | Lowest Price Target$61.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$77
Buy
3.18%
Upside
Reiterated
05/20/25
Novo Nordisk's strong financial performance and positive earnings call significantly bolster its stock score. The company's efficient operations, solid growth, and strategic initiatives are key strengths. Technical analysis suggests a cautious outlook with mixed trends, while valuation appears fair in the current market. Despite some challenges, the overall prospects remain robust.
BMO Capital
$64
Hold
-14.24%
Downside
Reiterated
05/19/25
TD Cowen
―
Buy
―
Reiterated
05/07/25
HSBC
$160→$102
Buy
36.67%
Upside
Reiterated
04/28/25
Guggenheim
―
Hold
―
Downgraded
04/17/25
Exane BNP Paribas
$61
Sell
-18.26%
Downside
Initiated
04/15/25
Bank of America Securities
$139.25
Buy
86.59%
Upside
Reiterated
03/28/25
Morgan Stanley
$99
Hold
32.65%
Upside
Reiterated
03/27/25
Unknown AnalystBerenberg Bank
Not Ranked
Berenberg Bank
$100→$90
Hold
20.59%
Upside
Reiterated
03/24/25
Unknown AnalystStifel Nicolaus
Not Ranked
Stifel Nicolaus
―
Hold
―
Downgraded
03/03/25
CFRA
$122→$90
Hold
20.59%
Upside
Reiterated
01/21/25
Argus Research
―
Buy
―
Reiterated
01/16/25
Argus Research Remains a Buy on Novo Nordisk (NVO)We are reiterating our BUY rating of Novo Nordisk A/S (NYSE: NVO). Novo, based in Denmark, is a diversified mega- cap pharmaceutical company with fast-growing hormone treatments for diabetes and obesity. The company is working with regulators on new indications for its GLP-1 treatments and is also focused on launching new products. The company has a robust new product pipeline that includes Phase 3 candidates such as new formulations of its blockbuster GLP-1 treatment, semaglutide, for diabetes and obesity; combination obesity therapies that include semaglutide; new semaglutide indications for Alzheimer’s disease and metabolic dysfunction-associated steatohepatitis (MASH); and new drugs for hemophilia, chronic kidney disease (CKD), heart failure, and cardiovascular disease. The balance sheet is clean and management has a history of growing the dividend and buying back stock.
Goldman Sachs
$148→$124
Buy
66.15%
Upside
Reiterated
01/13/25
Jefferies
$81.5
Sell
9.21%
Upside
Reiterated
12/20/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$77
Buy
3.18%
Upside
Reiterated
05/20/25
Novo Nordisk's strong financial performance and positive earnings call significantly bolster its stock score. The company's efficient operations, solid growth, and strategic initiatives are key strengths. Technical analysis suggests a cautious outlook with mixed trends, while valuation appears fair in the current market. Despite some challenges, the overall prospects remain robust.
BMO Capital
$64
Hold
-14.24%
Downside
Reiterated
05/19/25
TD Cowen
―
Buy
―
Reiterated
05/07/25
HSBC
$160→$102
Buy
36.67%
Upside
Reiterated
04/28/25
Guggenheim
―
Hold
―
Downgraded
04/17/25
Exane BNP Paribas
$61
Sell
-18.26%
Downside
Initiated
04/15/25
Bank of America Securities
$139.25
Buy
86.59%
Upside
Reiterated
03/28/25
Morgan Stanley
$99
Hold
32.65%
Upside
Reiterated
03/27/25
Unknown AnalystBerenberg Bank
Not Ranked
Berenberg Bank
$100→$90
Hold
20.59%
Upside
Reiterated
03/24/25
Unknown AnalystStifel Nicolaus
Not Ranked
Stifel Nicolaus
―
Hold
―
Downgraded
03/03/25
CFRA
$122→$90
Hold
20.59%
Upside
Reiterated
01/21/25
Argus Research
―
Buy
―
Reiterated
01/16/25
Argus Research Remains a Buy on Novo Nordisk (NVO)We are reiterating our BUY rating of Novo Nordisk A/S (NYSE: NVO). Novo, based in Denmark, is a diversified mega- cap pharmaceutical company with fast-growing hormone treatments for diabetes and obesity. The company is working with regulators on new indications for its GLP-1 treatments and is also focused on launching new products. The company has a robust new product pipeline that includes Phase 3 candidates such as new formulations of its blockbuster GLP-1 treatment, semaglutide, for diabetes and obesity; combination obesity therapies that include semaglutide; new semaglutide indications for Alzheimer’s disease and metabolic dysfunction-associated steatohepatitis (MASH); and new drugs for hemophilia, chronic kidney disease (CKD), heart failure, and cardiovascular disease. The balance sheet is clean and management has a history of growing the dividend and buying back stock.
Goldman Sachs
$148→$124
Buy
66.15%
Upside
Reiterated
01/13/25
Jefferies
$81.5
Sell
9.21%
Upside
Reiterated
12/20/24
Best Analysts Covering Novo Nordisk
1 Month
xxx
Success Rate
9/15 ratings generated profit
Average Return
+1.09%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +1.09% per trade.
3 Months
xxx
Success Rate
13/24 ratings generated profit
Average Return
+0.72%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.17% of your transactions generating a profit, with an average return of +0.72% per trade.
1 Year
Success Rate
9/24 ratings generated profit
Average Return
-1.59%
reiterated a buy rating 2 months ago
Copying Sachin Jain's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -1.59% per trade.
2 Years
xxx
Success Rate
4/15 ratings generated profit
Average Return
-6.57%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 26.67% of your transactions generating a profit, with an average return of -6.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NVO Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
2
1
2
4
3
Buy
13
11
11
6
5
Hold
5
5
8
8
11
Sell
1
1
0
1
1
Strong Sell
0
0
0
0
0
total
21
18
21
19
20
Each month's total comprises the sum of three months' worth of ratings.
NVO Financial Forecast
NVO Stock Forecast FAQ
What is NVO’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is 92.54.
What is NVO’s upside potential, based on the analysts’ average price target?
Novo Nordisk has 24.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NVO a Buy, Sell or Hold?
Novo Nordisk has a consensus rating of Hold which is based on 3 buy ratings, 4 hold ratings and 1 sell ratings.
What is Novo Nordisk’s price target?
The average price target for Novo Nordisk is 92.54. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $139.25 ,the lowest forecast is $61.00. The average price target represents 24.00% Increase from the current price of $74.63.
The highest analyst price target is $139.25 ,the lowest forecast is $61.00. The average price target represents 24.00% Increase from the current price of $74.63.
What do analysts say about Novo Nordisk?
Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of NVO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.